Cemdisiran
As of the edition of 20 October 2026, Cemdisiran is an oligonucleotide: in active development; acts on C5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Oligonucleotide
- Registered trials
- 14, 4 stopped early
- Disease areas
- Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Immune system; Cancer; Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 1 company on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Cemdisiran.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company is on route A because of Cemdisiran.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| C5 | Complement C5 | P01031 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 5 | 2 | 0 | 3 |
| Phase 3 | 6 | 0 | 5 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Alnylam Pharmaceuticals | Lead sponsor of trials | 2017 to now |
| Regeneron | Lead sponsor of trials | 2024 to now |